Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an update.
Alligator Bioscience has commented on Shanghai Henlius Biotech’s recent regulatory approval in China to begin Phase 2/3 trials of HLX22, a monoclonal antibody for treating HER2-positive breast cancer. Although Alligator is not directly involved in the development, the company stands to benefit financially from potential future revenues due to its licensing agreement with AbClon, which entitles Alligator to a share of Henlius’ revenues from HLX22.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs, particularly targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive nature of the tumor microenvironment, offering significant potential benefits for cancer patients across various cancer types. The company’s lead drug candidate, mitazalimab, is poised for Phase 3 development, having shown promising survival data in metastatic pancreatic cancer patients during Phase 2 trials. Alligator Bioscience is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Average Trading Volume: 4,555,968
Technical Sentiment Signal: Sell
Current Market Cap: SEK276M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.